• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.

作者信息

Suarez-Pinzon W L, Cembrowski G S, Rabinovitch A

出版信息

Diabetologia. 2009 Aug;52(8):1680-2. doi: 10.1007/s00125-009-1390-z. Epub 2009 May 20.

DOI:10.1007/s00125-009-1390-z
PMID:19455306
Abstract
摘要

相似文献

1
Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice.二肽基肽酶-4抑制剂与质子泵抑制剂联合治疗可恢复非肥胖糖尿病小鼠的正常血糖水平。
Diabetologia. 2009 Aug;52(8):1680-2. doi: 10.1007/s00125-009-1390-z. Epub 2009 May 20.
2
Reversal of new-onset diabetes through modulating inflammation and stimulating beta-cell replication in nonobese diabetic mice by a dipeptidyl peptidase IV inhibitor.二肽基肽酶 IV 抑制剂通过调节炎症和刺激非肥胖型糖尿病小鼠β细胞复制逆转新发糖尿病。
Endocrinology. 2010 Jul;151(7):3049-60. doi: 10.1210/en.2010-0068. Epub 2010 May 5.
3
Effects of combination therapy with dipeptidyl peptidase-IV and histone deacetylase inhibitors in the non-obese diabetic mouse model of type 1 diabetes.二肽基肽酶-4 和组蛋白去乙酰化酶抑制剂联合治疗在 1 型糖尿病非肥胖糖尿病小鼠模型中的作用。
Clin Exp Immunol. 2013 Jun;172(3):375-82. doi: 10.1111/cei.12068.
4
Dipeptidyl peptidase IV inhibitor improves the salivary gland histology of spontaneously diabetic mice.二肽基肽酶 IV 抑制剂改善自发性糖尿病小鼠的唾液腺组织学。
Arch Oral Biol. 2013 Jul;58(7):755-61. doi: 10.1016/j.archoralbio.2012.09.015. Epub 2012 Oct 26.
5
Combination Therapy Reverses Hyperglycemia in NOD Mice With Established Type 1 Diabetes.联合疗法可逆转已患1型糖尿病的非肥胖糖尿病（NOD）小鼠的高血糖症。
Diabetes. 2015 Nov;64(11):3873-84. doi: 10.2337/db15-0164. Epub 2015 Jul 16.
6
Combined treatment of dipeptidyl peptidase-4 inhibitor and exercise training improves lipid profile in KK/Ta mice.二肽基肽酶-4抑制剂与运动训练联合治疗可改善KK/Ta小鼠的血脂水平。
Exp Physiol. 2019 Jul;104(7):1051-1060. doi: 10.1113/EP087449. Epub 2019 May 22.
7
Dreams for type 1 diabetes: shutting off autoimmunity and stimulating beta-cell regeneration.1型糖尿病的梦想：关闭自身免疫并刺激β细胞再生。
Endocrinology. 2010 Jul;151(7):2971-3. doi: 10.1210/en.2010-0538.
8
Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor induces β-cell neogenesis from adult human pancreatic duct cells implanted in immunodeficient mice.二肽基肽酶-4 抑制剂与质子泵抑制剂联合治疗可诱导免疫缺陷小鼠体内植入的成人胰腺导管细胞产生胰岛β细胞新生。
Cell Transplant. 2011;20(9):1343-9. doi: 10.3727/096368910X557263. Epub 2011 Mar 8.
9
Dipeptidyl peptidase-4 inhibitor ameliorates early renal injury through its anti-inflammatory action in a rat model of type 1 diabetes.二肽基肽酶-4 抑制剂通过其在 1 型糖尿病大鼠模型中的抗炎作用改善早期肾损伤。
Biochem Biophys Res Commun. 2014 Jan 17;443(3):828-33. doi: 10.1016/j.bbrc.2013.12.049. Epub 2013 Dec 14.
10
RBx-0597, a potent, selective and slow-binding inhibitor of dipeptidyl peptidase-IV for the treatment of type 2 diabetes.RBx-0597，一种强效、选择性和慢结合的二肽基肽酶-4 抑制剂，用于治疗 2 型糖尿病。
Eur J Pharmacol. 2011 Feb 10;652(1-3):157-63. doi: 10.1016/j.ejphar.2010.06.001. Epub 2010 Jun 9.

引用本文的文献

1
Disease-modifying pharmacological treatments of type 1 diabetes: Molecular mechanisms, target checkpoints, and possible combinatorial treatments.1型糖尿病的疾病修饰性药物治疗：分子机制、靶点检查点及可能的联合治疗
Pharmacol Rev. 2025 Mar;77(2):100044. doi: 10.1016/j.pharmr.2025.100044. Epub 2025 Jan 23.
2
Association Between Clinical Use of Lansoprazole and the Risk of Coronary Heart Disease: A Nationwide Pharmacoepidemiological Cohort Study.兰索拉唑的临床使用与冠心病风险之间的关联：一项全国性药物流行病学队列研究。
Cardiovasc Drugs Ther. 2024 Dec 13. doi: 10.1007/s10557-024-07643-4.
3
Efficacy of combination therapy with GABA, a DPP-4i and a PPI as an adjunct to insulin therapy in patients with type 1 diabetes.

本文引用的文献

1
Dipeptidyl peptidase IV inhibition with MK0431 improves islet graft survival in diabetic NOD mice partially via T-cell modulation.使用MK0431抑制二肽基肽酶IV可部分通过调节T细胞来提高糖尿病NOD小鼠胰岛移植的存活率。
Diabetes. 2009 Mar;58(3):641-51. doi: 10.2337/db08-1101. Epub 2008 Dec 10.
2
Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice.胰高血糖素样肽-1与胃泌素联合治疗可使糖尿病非肥胖糖尿病（NOD）小鼠恢复正常血糖水平。
Diabetes. 2008 Dec;57(12):3281-8. doi: 10.2337/db08-0688. Epub 2008 Oct 3.
3
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes.
GABA、DPP-4i 和 PPI 联合治疗作为 1 型糖尿病胰岛素治疗辅助手段的疗效。
Front Endocrinol (Lausanne). 2023 May 24;14:1171886. doi: 10.3389/fendo.2023.1171886. eCollection 2023.
4
Triple drug therapy with GABA, sitagliptin, and omeprazole prevents type 1 diabetes onset and promotes its reversal in non-obese diabetic mice.GABA、西他列汀和奥美拉唑三联药物疗法可预防 1 型糖尿病的发生，并促进非肥胖型糖尿病小鼠的逆转。
Front Endocrinol (Lausanne). 2022 Oct 21;13:1028114. doi: 10.3389/fendo.2022.1028114. eCollection 2022.
5
Continuous stimulation of dual-function peptide PGLP-1-VP inhibits the morbidity and mortality of NOD mice through anti-inflammation and immunoregulation.双功能肽 PGLP-1-VP 的持续刺激通过抗炎和免疫调节抑制 NOD 小鼠的发病率和死亡率。
Sci Rep. 2021 Feb 11;11(1):3593. doi: 10.1038/s41598-021-83201-4.
6
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.二肽基肽酶 4 抑制剂及其潜在的免疫调节功能。
Pharmacol Ther. 2020 May;209:107503. doi: 10.1016/j.pharmthera.2020.107503. Epub 2020 Feb 14.
7
Regulation of adipocyte differentiation and metabolism by lansoprazole.兰索拉唑对脂肪细胞分化和代谢的调节作用。
Life Sci. 2019 Dec 15;239:116897. doi: 10.1016/j.lfs.2019.116897. Epub 2019 Oct 20.
8
New Insights into Immunotherapy Strategies for Treating Autoimmune Diabetes.免疫疗法治疗自身免疫性糖尿病的新见解。
Int J Mol Sci. 2019 Sep 26;20(19):4789. doi: 10.3390/ijms20194789.
9
Dipeptidyl peptidase-4(DPP-4) inhibitors: promising new agents for autoimmune diabetes.二肽基肽酶-4（DPP-4）抑制剂：自身免疫性糖尿病有前途的新药。
Clin Exp Med. 2018 Nov;18(4):473-480. doi: 10.1007/s10238-018-0519-0. Epub 2018 Jul 17.
10
DPP-4 Inhibitors as Treatments for Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis.DPP-4 抑制剂治疗 1 型糖尿病：系统评价和荟萃分析。
J Diabetes Res. 2018 Jan 8;2018:5308582. doi: 10.1155/2018/5308582. eCollection 2018.
肠促胰岛素系统：2型糖尿病中的胰高血糖素样肽-1受体激动剂和二肽基肽酶-4抑制剂
Lancet. 2006 Nov 11;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5.
4
Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes.使用西他列汀类似物对二肽基肽酶 -4 进行慢性抑制可在 2 型糖尿病啮齿动物模型中保留胰腺β细胞质量和功能。
Diabetes. 2006 Jun;55(6):1695-704. doi: 10.2337/db05-1602.
5
Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4.通过抗淋巴细胞血清和艾塞那肽-4短暂治疗治愈非肥胖糖尿病（NOD）小鼠的显性糖尿病。
Diabetes. 2004 Jul;53(7):1700-5. doi: 10.2337/diabetes.53.7.1700.
6
Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors.双肠促胰岛素受体敲除（DIRKO）小鼠揭示了肠胰岛轴在传导二肽基肽酶-IV抑制剂的血糖调节作用中的重要作用。
Diabetes. 2004 May;53(5):1326-35. doi: 10.2337/diabetes.53.5.1326.
7
Randomized prospective trial of the effect of induced hypergastrinemia on the prevention of pancreatic atrophy after pancreatoduodenectomy in humans.诱导高胃泌素血症对人类胰十二指肠切除术后预防胰腺萎缩作用的随机前瞻性试验。
Ann Surg. 2003 Apr;237(4):522-9. doi: 10.1097/01.SLA.0000059985.56982.11.
8
Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.二肽基肽酶IV抑制剂治疗可刺激链脲佐菌素诱导的糖尿病大鼠的β细胞存活和胰岛新生。
Diabetes. 2003 Mar;52(3):741-50. doi: 10.2337/diabetes.52.3.741.
9
Role of endogenous hypergastrinemia in regenerating endocrine pancreas after partial pancreatectomy.内源性高胃泌素血症在胰腺部分切除术后内分泌胰腺再生中的作用。
Dig Dis Sci. 1996 Dec;41(12):2433-9. doi: 10.1007/BF02100139.
10
Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV.二肽基肽酶IV在体外和体内对葡萄糖依赖性促胰岛素多肽和截短的胰高血糖素样肽1的降解作用。
Endocrinology. 1995 Aug;136(8):3585-96. doi: 10.1210/endo.136.8.7628397.